EXECUTIVE INTERVIEWS

  • What Makes Roche’s Approach To Partnering Unusual
    What Makes Roche’s Approach To Partnering Unusual

    Sophie Kornowski-Bonnet, Roche’s head of partnering, also serves on the company’s senior leadership team — a rarity among top biopharma companies. But that’s not the only unusual fact about Roche’s approach to partnering.

  • From Startup To Acquisition By Lilly, And Everything In Between
    From Startup To Acquisition By Lilly, And Everything In Between

    “Going to medical school, completing my residency, and pursuing my Ph.D. were a cake walk in comparison to being the CEO of a biotech,” says Daniel Skovronsky, M.D., Ph.D., who talks about his journey from working out of his car to selling his company for $300 million and then going to work for Lilly.

  • A Name Change — And More — For A Biotech
    A Name Change — And More — For A Biotech

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

  • Can David Hung Lead Axovant To Alzheimer’s Success?
    Can David Hung Lead Axovant To Alzheimer’s Success?

    Why would David Hung, M.D., a veteran pharma executive, forgo retirement (after a big acquisition payday), join Axovant Sciences, and then invest $10 million of his own money into the small company? Our chief editor sat down with him to get the answers to those questions and more.

  • Cytokinetics: Keeping Its Sights On Independence
    Cytokinetics: Keeping Its Sights On Independence

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

  • Reaching A Turning Point With An Unusual Cancer Therapeutic
    Reaching A Turning Point With An Unusual Cancer Therapeutic

    Sometimes it pays to go against the grain. In 2013 Life Science Leader published an article describing the efforts of Dr. Ray Takigiku to establish Bexion Pharmaceuticals, a startup biotechnology firm, located in Covington, KY.

  • Behind The Scenes Of Allergan’s Social Contract
    Behind The Scenes Of Allergan’s Social Contract

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  • P3s: How To Get The Good …Without The Bad
    P3s: How To Get The Good …Without The Bad

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  • Sanat Chattopadhyay — Shaping Merck’s Manufacturing Future
    Sanat Chattopadhyay — Shaping Merck’s Manufacturing Future

    It’s been a little over a year since Sanat Chattopadhyay was named president of Merck Manufacturing Division (MMD), and this month he gives an exclusive interview on the status of the division’s transformational turnaround.

  • Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion
    Chasing Invention: Jeffrey Kindler At The Helm Of Centrexion

    As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.

  • Rising Out Of Takeda’s Reorganization: New Materials & Innovation
    Rising Out Of Takeda’s Reorganization: New Materials & Innovation

    “You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.

  • Ipsen In The USA — Building & Leading The Subsidiary As Startup
    Ipsen In The USA — Building & Leading The Subsidiary As Startup

    Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.

  • CEOs 40 & Under: The Future of Pharma Innovation
    CEOs 40 & Under: The Future of Pharma Innovation

    To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.

  • Astellas Puts Oncology Front & Center
    Astellas Puts Oncology Front & Center

    Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.

More executive interviews

BEYOND THE PRINTED PAGE

  • A Woman Leader On The Subject Of Women As Leaders

    Can women leaders be responsible and liked – at the same time? Sophie Kornowski-Bonnet, head of Roche partnering, discusses her approach to overcoming adversity, leading to an interesting discussion on if there are differences beyond gender for male versus female executives.

  • The Intriguing Career Path Of Roche’s Head Of Partnering

    What’s it take to get to the c-suite of a biopharmaceuticals company? For Sophie Kornowski-Bonnet, it was a willingness to step out of her comfort zone. The current head of Roche partnering and executive committee member, shares her intriguing career path, which began in Paris, France, back in 1986.

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Prior to joining Lilly as SVP of clinical and product development, Daniel Skovronsky, M.D., Ph.D. was CEO of Avid Radiopharmaceuticals — a company he founded while still a graduate student. This article is a prequel to the upcoming feature in our November issue that explores how he built a $300 million company.

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

More From Life Science Leader Blogs

@LIFESCILEADER1